Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
NCT00095433
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Macular Degeneration
Interventions
DRUG:
rhuFab V2 (ranibizumab)
Sponsor
Genentech, Inc.